Yara Yakoub, Fernando Gonzalez-Ortiz, Nicholas J. Ashton, Christine Déry, Cherie Strikwerda-Brown, Frédéric St-Onge, Valentin Ourry, Michael Schöll, Maiya R. Geddes, Simon Ducharme, Maxime Montembeault, Pedro Rosa-Neto, Jean-Paul Soucy, John C. S. Breitner, Henrik Zetterberg, Kaj Blennow, Judes Poirier, Sylvia Villeneuve, PREVENT−AD Research Group
{"title":"血浆 p-tau217 能识别认知功能正常、但在 10 年内会出现认知障碍的老年人","authors":"Yara Yakoub, Fernando Gonzalez-Ortiz, Nicholas J. Ashton, Christine Déry, Cherie Strikwerda-Brown, Frédéric St-Onge, Valentin Ourry, Michael Schöll, Maiya R. Geddes, Simon Ducharme, Maxime Montembeault, Pedro Rosa-Neto, Jean-Paul Soucy, John C. S. Breitner, Henrik Zetterberg, Kaj Blennow, Judes Poirier, Sylvia Villeneuve, PREVENT−AD Research Group","doi":"10.1002/alz.14537","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>We assessed the prognostic accuracy of plasma p-tau217 in predicting the progression to mild cognitive impairment (MCI) in cognitively unimpaired (CU) individuals over a mean follow-up of 5.65 years after plasma collection (range 1.01–10.47).</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>We included 215 participants from the PREVENT−AD cohort with plasma Aβ<sub>42/40</sub> and p-tau217, 159 with cerebrospinal fluid (CSF) Aβ<sub>42/40</sub> and p-tau217, and 155 with <sup>18</sup>F-NAV4694 and <sup>18</sup>F-flortaucipir PET scans. MCI progression was determined by multidisciplinary consensus among memory experts blind to biomarker and genetic information.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>Cox proportional hazard models indicated a greater progression rate in A+T+<sub>plasma</sub> and A−T+<sub>plasma</sub> compared to A−T−<sub>plasma</sub> individuals (HR = 7.81 [95% CI = 3.92 to 15.59] and HR = 4.25 [1.60–11.31] respectively). Similar results were found with CSF (HR = 3.63 [1.72–7.70]) and PET (HR = 9.30 [3.67–23.55]).</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>Plasma p-tau217 is a prognostic marker for identifying individuals who will develop cognitive impairment within ten years.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Elevated plasma p-tau217 levels in CU individuals indicate future clinical progression.</li>\n \n <li>Adding plasma Aβ<sub>42/40</sub> status to p-tau markers did not improve the prediction to MCI.</li>\n \n <li>All individuals with abnormal tau PET measured in a temporal meta-ROI progressed to MCI.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 2","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.14537","citationCount":"0","resultStr":"{\"title\":\"Plasma p-tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10-year window\",\"authors\":\"Yara Yakoub, Fernando Gonzalez-Ortiz, Nicholas J. Ashton, Christine Déry, Cherie Strikwerda-Brown, Frédéric St-Onge, Valentin Ourry, Michael Schöll, Maiya R. Geddes, Simon Ducharme, Maxime Montembeault, Pedro Rosa-Neto, Jean-Paul Soucy, John C. S. Breitner, Henrik Zetterberg, Kaj Blennow, Judes Poirier, Sylvia Villeneuve, PREVENT−AD Research Group\",\"doi\":\"10.1002/alz.14537\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> INTRODUCTION</h3>\\n \\n <p>We assessed the prognostic accuracy of plasma p-tau217 in predicting the progression to mild cognitive impairment (MCI) in cognitively unimpaired (CU) individuals over a mean follow-up of 5.65 years after plasma collection (range 1.01–10.47).</p>\\n </section>\\n \\n <section>\\n \\n <h3> METHODS</h3>\\n \\n <p>We included 215 participants from the PREVENT−AD cohort with plasma Aβ<sub>42/40</sub> and p-tau217, 159 with cerebrospinal fluid (CSF) Aβ<sub>42/40</sub> and p-tau217, and 155 with <sup>18</sup>F-NAV4694 and <sup>18</sup>F-flortaucipir PET scans. MCI progression was determined by multidisciplinary consensus among memory experts blind to biomarker and genetic information.</p>\\n </section>\\n \\n <section>\\n \\n <h3> RESULTS</h3>\\n \\n <p>Cox proportional hazard models indicated a greater progression rate in A+T+<sub>plasma</sub> and A−T+<sub>plasma</sub> compared to A−T−<sub>plasma</sub> individuals (HR = 7.81 [95% CI = 3.92 to 15.59] and HR = 4.25 [1.60–11.31] respectively). Similar results were found with CSF (HR = 3.63 [1.72–7.70]) and PET (HR = 9.30 [3.67–23.55]).</p>\\n </section>\\n \\n <section>\\n \\n <h3> DISCUSSION</h3>\\n \\n <p>Plasma p-tau217 is a prognostic marker for identifying individuals who will develop cognitive impairment within ten years.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Highlights</h3>\\n \\n <div>\\n <ul>\\n \\n <li>Elevated plasma p-tau217 levels in CU individuals indicate future clinical progression.</li>\\n \\n <li>Adding plasma Aβ<sub>42/40</sub> status to p-tau markers did not improve the prediction to MCI.</li>\\n \\n <li>All individuals with abnormal tau PET measured in a temporal meta-ROI progressed to MCI.</li>\\n </ul>\\n </div>\\n </section>\\n </div>\",\"PeriodicalId\":7471,\"journal\":{\"name\":\"Alzheimer's & Dementia\",\"volume\":\"21 2\",\"pages\":\"\"},\"PeriodicalIF\":13.0000,\"publicationDate\":\"2025-02-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.14537\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer's & Dementia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/alz.14537\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/alz.14537","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Plasma p-tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10-year window
INTRODUCTION
We assessed the prognostic accuracy of plasma p-tau217 in predicting the progression to mild cognitive impairment (MCI) in cognitively unimpaired (CU) individuals over a mean follow-up of 5.65 years after plasma collection (range 1.01–10.47).
METHODS
We included 215 participants from the PREVENT−AD cohort with plasma Aβ42/40 and p-tau217, 159 with cerebrospinal fluid (CSF) Aβ42/40 and p-tau217, and 155 with 18F-NAV4694 and 18F-flortaucipir PET scans. MCI progression was determined by multidisciplinary consensus among memory experts blind to biomarker and genetic information.
RESULTS
Cox proportional hazard models indicated a greater progression rate in A+T+plasma and A−T+plasma compared to A−T−plasma individuals (HR = 7.81 [95% CI = 3.92 to 15.59] and HR = 4.25 [1.60–11.31] respectively). Similar results were found with CSF (HR = 3.63 [1.72–7.70]) and PET (HR = 9.30 [3.67–23.55]).
DISCUSSION
Plasma p-tau217 is a prognostic marker for identifying individuals who will develop cognitive impairment within ten years.
Highlights
Elevated plasma p-tau217 levels in CU individuals indicate future clinical progression.
Adding plasma Aβ42/40 status to p-tau markers did not improve the prediction to MCI.
All individuals with abnormal tau PET measured in a temporal meta-ROI progressed to MCI.
期刊介绍：
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
